# DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas

Source: https://onco.cc/trials/nct00805376/  
OnCo record `nct00805376` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of DNX-2401 run by DNAtrix, Inc., completed.

## Summary

DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas is a phase 1 interventional study registered as NCT00805376 by DNAtrix, Inc., with 37 participants enrolled, started 2009-02. Conditions recorded: Brain Cancer and Central Nervous System Diseases. Interventions recorded: DNX-2401 and Tumor Removal.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00805376
- Phase: 1
- Setting: Phase I Trial of Conditionally Replication-Competent Adenovirus (DNX-2401, Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas
- Sponsor: DNAtrix, Inc.
- Enrolled: 37

## Sources

- ClinicalTrials.gov NCT00805376: https://clinicaltrials.gov/study/NCT00805376

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/)
- drugs: [DNX-2401](https://onco.cc/drugs/dnx-2401/)
- companies: [DNAtrix](https://onco.cc/companies/dnatrix/)

---
JSON: https://onco.cc/api/v1/entities/nct00805376.json